Patent classifications
A23L29/06
AMYLASE COMPOSITION
The present invention provides an amylase composition which enables long-term stable storage of amylase without using chemicals that may affect the human body in food use. The present invention relates to an amylase composition containing a saccharide containing glucose as a constituent unit, a polyhydric alcohol, and an amylase.
SUPER-OXIDE DISMUTASE SOLUBLE FIBER COMPOSITIONS
Provided are compositions comprising super-oxide dismutase and a soluble fiber. The compositions may additionally comprise other antioxidants, vitamins and nutrients, The compositions can be used as dietary supplements and for improving health and well-being.
HIGH MOISTURE EDIBLE COMPOSITIONS AND METHODS OF PREPARATION THEREOF
The present invention is direct to an edible composition in which fruit, vegetables and/or nuts, in conjunction with a hydrocolloid, are treated with pressure and/or heat to form an edible composition that is dimensionally stable, ambient stable for at least 12 months, has a moisture content greater than 50 wt. %, has a pH less than 4.5, has a water activity greater than 0.5, is commercially sterile, is free of artificial flavors, has a solids content greater than 10 wt. %, and does not exhibit syneresis. Also provided is a method for preparation of the edible composition.
PICHIA PASTORIS MUTANT STRAIN FOR EXPRESSING EXOGENOUS GENE
Provided is a Pichia pastoris mutant strain for expressing an exogenous gene. Specifically, provided is a Pichia pastoris mutant strain comprising, with respect to Pichia pastoris mutant strain GS115 or CICC32806, one or more of the following six mutations: BQ9382_C1-2260, EKK deletions at positions 308-310, a hypothetical protein; BQ9382_C1-3800, E129K, 60S ribosomal subunit assembly/exported protein LOC1; BQ9382_C1-5700, I312M, mitochondrial external NADH dehydrogenase, type II NAD(P)H:quinone oxidoreductase; BQ9382_C2-3950, Q145X, an essential protein having a binding partner Psr1p and used for completely activating a general stress response; BQ9382_C3-2220, E188K, a hypothetical protein; and BQ9382_C3-4370, W196X, orotidine 5\′-phosphate decarboxylase. The provided Pichia pastoris mutant strain is an effective commonly employed host for exogenous expression, and can efficiently express different proteins, especially phospholipase and lipase.
A Low Cost Biodegradable Drinking Straw
A low cost biodegradable drinking straw comprising structurally non-altered corn starch mixed with one or more than one improver. The improver comprises a biological enzyme preparation and a colloid preparation. The low cost biodegradable drinking straw is made by providing 98% structurally non-altered corn starch mixed with one or more than one improver to make a biodegradable powder. The edible biodegradable powder is formed into a drinking straw shape and extruded to a drinking straw shape. When the extruded drinking straw shapes are cooled, they are cut into an appropriate drinking straw length. The cut drinking straws are then dried and packaged.
Alkaline phosphatase agents for treatment of neurodevelopmental disorders
Compositions and methods, including therapeutic alkaline phosphatases that find use in the treatment or prevention of various neurodevelopmental diseases or disorders, are described.
MUTANT TRANSGLUTAMINASE
A mutant transglutaminase (mutant TG) having high thermostability and/or high pH stability is provided. A mutant TG having a mutation at amino acid residue(s) such as D1, Y24, R48, S101, G102, N139, D142, L147, K152, G157, R167, N176, K181, E182, H188, D189, R208, T245, S246, G250, G275, S284, H289, G301, and K327 and/or a mutation of introducing a disulfide bond.
Material for de-dusting granular enzyme preparations
The invention relates to a granular de-dusting material comprising 30-60 wt. % cold-swelling potato starch, 5-40 wt. % vegetable oil, 5-35 wt. % flour, all weight percentages based on dry weight of the granular de-dusting material. The invention further relates to a method for preparing a de-dusted enzyme product, comprising contacting a granular enzyme preparation, containing dust particles, with a granular dedusting material according to the invention, whereby the dust particles adhere to the granular de-dusting material, whereby the de-dusted enzyme product is obtained. The invention further relates to a de-dusted enzyme product.
Method for producing fermented blood sausage with high antioxidant activity
Provided is a method for producing fermented blood sausage having high antioxidant activity, comprising (1) preparing hemoglobin antioxidant peptide through Plastein reaction; (2) brining and primarily fermenting livestock or poultry meat; (3) deodoring and breaking livestock or poultry blood; (4) filling and secondary fermentation; (5) obtaining a finished product after drying. Compared with prior arts, the present disclosure uses Plastein reaction of blood to prepare a highly active antioxidant peptide, the fermented blood sausage has a total antioxidant capacity up to 6.89 U/mg protein, with an increase rate of 58%. The blood was deodorized, and total amount of free amino acids in secondary fermentation by lactic acid bacteria in combination with yeasts reached 12.74 mg/g, with an increase rate of 42%, providing the fermented blood sausage with better flavor and chewiness. The present disclosure also provides a new approach to comprehensive utilization of livestock or poultry blood resources.
COMPOSITION FOR PREVENTING OR TREATING NEUROINFLAMMATORY DISORDERS, COMPRISING BEE VENOM EXTRACT AS ACTIVE INGREDIENT
The present invention relates to a composition for preventing or treating neuroinflammatory disorders, comprising a bee venom extract as an active ingredient. More specifically, the present invention provides a pharmaceutical composition or a health functional food composition for preventing or treating neuroinflammatory disorders, both of which comprise, as an active ingredient, a bee venom extract in which the amount of phospholipase A2 (PLA2) is 50 to 85%. The bee venom extract alleviates decreased motor functions caused by neurotoxicity and has neuroprotective and neuroinflammation-relieving effects, thereby enabling the prevention or treatment of neuroinflammatory disorders. Particularly, a pharmaceutical composition according to the present invention can further improve an effect of preventing or treating neuroinflammatory disorders by being subcutaneously administered or by being co-administered with a STAT3 inhibitor or an NF-κB inhibitor, thereby enabling more effective prevention or treatment of neuroinflammatory disorders.